Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $46.43M (cash outflow) fell 9.9% year over year, ahead of the -41.1% change in trailing-twelve-month operating cash flow. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at -12.1% a year.
Context
- Operating cash flow amounted to 100.5% of revenue in FY2025, down 40.2 pp from a year earlier.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.9% holds above the trailing-twelve-month pace of -41.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (171.06M) USD
- Year-over-year change
- +46.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (171.06M) | +46.5% |
| FY2024 | 2024-12-31 | (319.59M) | -8.2% |
| FY2023 | 2023-12-31 | (295.5M) | -17.2% |
| FY2022 | 2022-12-31 | (252.2M) | +0.6% |
| FY2021 | 2021-12-31 | (253.82M) | — |
Operating Cash Flow vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -41.1% is the 9th highest of 10, against a peer median of +19.4%.
- Operating cash flow amounts to 117.5% of revenue for DNA, versus a peer median of 46.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $446.05M USD | +7.5% | — | 681.0% | |
| LTM Dec 2025 | $277.91M USD | +50.5% | +32.7% | — | |
| LTM Mar 2026 | $254.1M USD | +1.4% | +0.0% | 284.2% | |
| LTM Sep 2026 | $189.95M USD | -41.2% | +1.1% | 50.1% | |
| LTM Mar 2026 | $165.97M USD | -41.1% | -12.1% | 117.5% | |
| LTM Mar 2026 | $134.47M USD | +12.4% | +54.4% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $96.01M USD | +23.6% | +51.2% | — |
| LTM Mar 2026 | €67.49M EUR | +43.8% | -40.0% | 43.2% | |
| LTM Jun 2026 | $25.26M USD | +19.4% | — | 12.1% | |
| LTM Mar 2026 | $8.28M USD | +107.9% | -14.1% | 10.4% | |
| Peer median (excluding DNA) | — | +19.4% | +1.1% | 46.6% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.84B) | (2.11B) | (892.87M) | (547.03M) | (312.76M) |
| Depreciation & Amortization | 29.08M | 42.55M | 71.55M | 63.02M | 58.99M |
| Deferred Income Tax | 30.21M | (14.61M) | (801K) | (936K) | (1.36M) |
| Stock-Based Compensation | 1.61B | 1.93B | 229.88M | 112.34M | 81.55M |
| Change in Working Capital | (61.54M) | (37.01M) | 29.84M | (89.67M) | (44.09M) |
| Accounts Receivables | (114.09M) | 55.02M | 50.07M | (4.73M) | (1.47M) |
| Inventory | (626K) | 164K | 0 | 0 | 0 |
| Accounts Payables | (2.25M) | (10.84M) | (1.18M) | 4.77M | (2.99M) |
| Other Working Capital | 55.43M | (81.35M) | (19.05M) | (89.72M) | (39.62M) |
| Other Non-Cash Items | (20.95M) | (67.4M) | 266.9M | 142.69M | 46.62M |
| Operating Cash Flow | (253.82M) | (252.2M) | (295.5M) | (319.59M) | (171.06M) |
| Capital Expenditures | (56.52M) | (52.27M) | (40.8M) | (62.54M) | (7.67M) |
| Acquisitions (Net) | (12.04M) | 26.65M | (38.55M) | (5.4M) | 0 |
| Purchases of Investments | (5M) | (3.69M) | 0 | 0 | (418.63M) |
| Sales of Investments | 0 | 0 | 0 | 4.52M | 185.38M |
| Other Investing Activities | 304K | (38.08M) | (1.34M) | 1.19M | 624K |
| Investing Cash Flow | (73.26M) | (67.39M) | (80.69M) | (62.24M) | (240.29M) |
| Debt Repayment | (1.12M) | (1.24M) | (1.3M) | (897K) | (354K) |
| Common Stock Issued | 0 | 99.3M | 0 | 80K | 19.47M |
| Common Stock Repurchased | (25M) | 0 | (23K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.56B | (2.73M) | (1.43M) | (922K) | (1.34M) |
| Financing Cash Flow | 1.53B | 95.34M | (3.22M) | (1.74M) | 17.78M |
| Effect of Forex Changes | (19K) | 908K | (588K) | (281K) | 395K |
| Net Change in Cash | 1.21B | (223.35M) | (380M) | (383.84M) | (393.18M) |
| Free Cash Flow | (310.34M) | (304.47M) | (336.3M) | (382.13M) | (178.72M) |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.